Resonant Capital Advisors LLC Purchases 4,172 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Resonant Capital Advisors LLC raised its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 19.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,789 shares of the company’s stock after buying an additional 4,172 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Elanco Animal Health were worth $384,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of ELAN. JPMorgan Chase & Co. lifted its position in Elanco Animal Health by 15.6% during the first quarter. JPMorgan Chase & Co. now owns 355,004 shares of the company’s stock valued at $9,262,000 after acquiring an additional 47,881 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Elanco Animal Health by 11.8% during the 1st quarter. American Century Companies Inc. now owns 32,218 shares of the company’s stock valued at $841,000 after purchasing an additional 3,396 shares during the last quarter. US Bancorp DE lifted its holdings in shares of Elanco Animal Health by 17.5% during the 1st quarter. US Bancorp DE now owns 16,263 shares of the company’s stock valued at $425,000 after purchasing an additional 2,419 shares during the last quarter. Private Advisor Group LLC acquired a new stake in shares of Elanco Animal Health in the 1st quarter worth $333,000. Finally, MetLife Investment Management LLC purchased a new position in Elanco Animal Health during the 1st quarter worth $232,000. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $12.95 on Friday. The firm has a fifty day moving average price of $15.66 and a 200 day moving average price of $13.65. Elanco Animal Health Incorporated has a 1 year low of $7.88 and a 1 year high of $16.88. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 1.35.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Monday, February 26th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.02). The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.19 earnings per share. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ELAN shares. TheStreet raised Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Barclays upped their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Stifel Nicolaus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $13.00 to $20.00 in a research note on Friday, January 5th. The Goldman Sachs Group boosted their price objective on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a “sell” rating in a report on Tuesday, February 27th. Finally, Morgan Stanley raised their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director R David Hoover purchased 20,000 shares of Elanco Animal Health stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the transaction, the director now directly owns 185,000 shares in the company, valued at $2,985,900. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.40% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.